158 related articles for article (PubMed ID: 25676837)
1. Critical methodological factors in diagnosing minimal residual disease in hematological malignancies using quantitative PCR.
Nyvold CG
Expert Rev Mol Diagn; 2015 May; 15(5):581-4. PubMed ID: 25676837
[TBL] [Abstract][Full Text] [Related]
2. Assessment of a new RNA stabilizing reagent (Tempus Blood RNA) for minimal residual disease in onco-hematology using the EAC protocol.
Prezeau N; Silvy M; Gabert J; Picard C
Leuk Res; 2006 May; 30(5):569-74. PubMed ID: 16209886
[TBL] [Abstract][Full Text] [Related]
3. Quantitative monitoring of single nucleotide mutations by allele-specific quantitative PCR can be used for the assessment of minimal residual disease in patients with hematological malignancies throughout their clinical course.
Taira C; Matsuda K; Kamijyo Y; Sakashita K; Ishida F; Kumagai T; Yamauchi K; Okumura N; Honda T
Clin Chim Acta; 2011 Jan; 412(1-2):53-8. PubMed ID: 20849840
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease in hematological malignancies.
Raanani P; Hochhaus A
Acta Haematol; 2004; 112(1-2):5-7. PubMed ID: 15178998
[No Abstract] [Full Text] [Related]
5. [Detection of minimal residual disease in childhood hematological malignancies and its clinical significance].
Tang S; Lu S; Zhang X; Ran C; Huang D; Wei X
Zhonghua Xue Ye Xue Za Zhi; 2000 Jan; 21(1):27-9. PubMed ID: 11876957
[TBL] [Abstract][Full Text] [Related]
6. [The current status of genetic testing for leukemia].
Satoh Y; Masuda A; Yokota H; Yatomi Y
Rinsho Byori; 2014 Apr; 62(4):369-77. PubMed ID: 25022066
[TBL] [Abstract][Full Text] [Related]
7. [Minimal residual disease in hematology].
Rák K
Orv Hetil; 2001 May; 142(21):1091-5. PubMed ID: 11449837
[No Abstract] [Full Text] [Related]
8. [DNA diagnosis in hematological malignancies].
Nara N
Rinsho Byori; 2001 Mar; Suppl 115():37-44. PubMed ID: 11391935
[TBL] [Abstract][Full Text] [Related]
9. Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies.
Coccaro N; Tota G; Anelli L; Zagaria A; Specchia G; Albano F
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365599
[TBL] [Abstract][Full Text] [Related]
10. Methods of minimal residual disease (MRD) detection in childhood haematological malignancies.
Jółkowska J; Derwich K; Dawidowska M
J Appl Genet; 2007; 48(1):77-83. PubMed ID: 17272865
[TBL] [Abstract][Full Text] [Related]
11. Molecular hematology. Qualitative to quantitative techniques.
Khalil SH
Saudi Med J; 2005 Oct; 26(10):1516-22. PubMed ID: 16228048
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease testing in hematologic malignancies and solid cancer.
Ben Lassoued A; Nivaggioni V; Gabert J
Expert Rev Mol Diagn; 2014 Jul; 14(6):699-712. PubMed ID: 24938122
[TBL] [Abstract][Full Text] [Related]
13. Molecular diagnosis of hematopoietic and lymphoid neoplasms.
Jevremovic D; Viswanatha DS
Hematol Oncol Clin North Am; 2009 Aug; 23(4):903-33. PubMed ID: 19577174
[TBL] [Abstract][Full Text] [Related]
14. Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas.
Sørensen CD; Jørgensen JM; Nederby L; Hokland P; Nyvold CG
J Immunol Methods; 2014 Apr; 406():131-6. PubMed ID: 24631717
[TBL] [Abstract][Full Text] [Related]
15. Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies.
Ip BBK; Wong ATC; Law JHY; Au CH; Ma SY; Chim JCS; Liang RHS; Leung AYH; Wan TSK; Ma ESK
Sci Rep; 2024 Mar; 14(1):6400. PubMed ID: 38493200
[TBL] [Abstract][Full Text] [Related]
16. The multiparametric scanning system for evaluation of minimal residual disease in hematological malignancies.
Trakhtenbrot L; Rechavi G; Amariglio N
Acta Haematol; 2004; 112(1-2):24-9. PubMed ID: 15179001
[TBL] [Abstract][Full Text] [Related]
17. [Introduction to the molecular diagnostic methods of oncohematology].
Király AP; Alpár D; Fésüs V; Marosvári D; Matolcsy A; Bödör C
Magy Onkol; 2016 Jun; 60(2):88-98. PubMed ID: 27275635
[TBL] [Abstract][Full Text] [Related]
18. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
[TBL] [Abstract][Full Text] [Related]
19. Application of allele-specific quantitative PCR using genomic DNA to monitor minimal residual disease based on mutant gene levels following allogeneic hematopoietic stem cell transplantation in patients with hematological malignancies: comparison of mutant levels with autologous DNA percentage by short tandem repeat-PCR.
Taira C; Matsuda K; Saito S; Sakashita K; Sugano M; Okumura N; Honda T
Clin Chim Acta; 2012 Feb; 413(3-4):516-9. PubMed ID: 22138486
[TBL] [Abstract][Full Text] [Related]
20. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
Chan DW; Liang R; Kwong YL; Chan V
Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
